The Diagnosis and Management of Upper Gastrointestinal Cancer

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 2803

Special Issue Editor


E-Mail Website
Guest Editor
Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Mazandaran 48166-33131, Iran
Interests: gastric cancer; molecular epidemiology; cancer stem cell marker

Special Issue Information

Dear Colleagues,

Upper gastrointestinal cancers include oesophageal cancer, stomach cancer, small intestine cancer, pancreatic cancer, liver cancer, and gallbladder cancer. Some of these cancers had high mortality among all type of cancers. Based on the GLOBOCAN report, from 19,292,789 new cancer cases and 9,958,133 new cancer deaths in 2020, with these cancers representing 16.6% and 27.1%, respectively. Conventional method for these cancer diagnosis are invasive and usually detect patients in end stages. In addition to conventional methos, the new ways developed to diagnose of cancer such as biomarkers, genetic screening, pain-free breathalysers, artificial intelligence for medical diagnostics, etc., can help with the diagnosis and early detection of cancer. Thus, the development of diagnostic markers and the early diagnostic approaches of these cancers can improve the management and finally improve survival rates. This Special Issue aims to provide a comprehensive picture of the diagnosis and management of upper gastrointestinal cancer by conventional and new ways methods.

Dr. Reza Alizadeh-Navaei
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diagnosis
  • diagnostic
  • diagnose
  • early diagnosis
  • early detection
  • neoplasm staging
  • tumor staging
  • cancer staging
  • tnm staging
  • tnm classifications
  • esophageal neoplasm
  • esophagus cancer
  • esophageal cancer
  • stomach neoplasm
  • gastric neoplasm
  • gastric cancer
  • stomach cancer
  • small bowel cancer
  • intestinal neoplasm
  • intestines neoplasm
  • intestines cancer
  • intestinal cancer
  • pancreatic cancer
  • pancreatic neoplasm
  • pancreas neoplasm
  • pancreas cancer
  • liver cancer
  • liver neoplasm
  • hepatic neoplasm
  • hepatocellular cancer
  • hepatic cancer
  • gallbladder cancer
  • gallbladder neoplasm

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

14 pages, 10740 KiB  
Case Report
Metastatic Renal Cell Carcinoma to Pancreas: Case Series and Review of the Literature
by Daniel Vasile Balaban, Laura Coman, Flavius Stefan Marin, Marina Balaban, Daniela Tabacelia, Florina Vasilescu, Raluca Simona Costache and Mariana Jinga
Diagnostics 2023, 13(8), 1368; https://doi.org/10.3390/diagnostics13081368 - 7 Apr 2023
Cited by 5 | Viewed by 2259
Abstract
Metastasis to the pancreas represents a small proportion of all pancreatic malignancies. Among primary tumors that metastasize to the pancreas, renal cell carcinoma (RCC) is one of the most common causes of metastatic pancreatic lesions. We herein report a case series of three [...] Read more.
Metastasis to the pancreas represents a small proportion of all pancreatic malignancies. Among primary tumors that metastasize to the pancreas, renal cell carcinoma (RCC) is one of the most common causes of metastatic pancreatic lesions. We herein report a case series of three patients with pancreatic metastasis from RCC. The first is a 54-year-old male with a history of left nephrectomy for RCC, in whom an isthmic pancreatic mass suggestive of a neuroendocrine lesion was found during oncological follow-up. Endoscopic ultrasound (EUS)-guided fine needle biopsy (FNB) identified pancreatic metastasis of RCC and the patient was referred for surgery. The second case is a 61-year-old male, hypertensive, diabetic, with left nephrectomy for RCC six years previously, who complained of weight loss and was found with a hyperenhancing mass in the head of the pancreas and a lesion with a similar pattern in the gallbladder. EUS-FNB from the pancreas proved to be a metastatic pancreatic lesion. Cholecystectomy and treatment with tyrosine kinase inhibitors were recommended. The third case is a 68-year-old dialysis patient referred for evaluation of a pancreatic mass, also confirmed by EUS-FNB, who was started on sunitinib treatment. We report a literature summary on epidemiology and clinical features, diagnosis and differential diagnosis and treatment and outcomes in pancreatic metastasis of RCC. Full article
(This article belongs to the Special Issue The Diagnosis and Management of Upper Gastrointestinal Cancer)
Show Figures

Figure 1

Back to TopTop